|
|
||||||||







,
Departments of
* General and Thoracic Surgery, Pathology, Immunology, and
Internal Medicine, and
Center for Genetic and Cellular Therapies, Duke University Medical Center, Durham, North Carolina; and
Immunex Corporation, Seattle, Washington
Correspondence: Michael A. Morse, M.D., Duke University Medical Center, Box 3233, Durham, NC 27710. E-mail: m.morse{at}cgct.duke.edu
The ligand for the receptor tyrosine kinase fms-like tyrosine kinase 3
(Flt3L) is a growth factor for hematopoietic progenitors and induces
expansion of the two distinct lineages of dendritic cells (DC) that
have been described in humans. These two lineages, DC1 and DC2, have
been described according to their ability to induce naive T cell
differentiation to T helper cell type 1 (Th1) and Th2 effector cells,
respectively. The immunoregulatory potential of DC1 and DC2 depends on
their state of maturation and activation, which can be mediated by
several molecules. Because monocyte-derived DC1 produce interleukin-12
(IL-12) when stimulated with CD40 ligand (CD40L), we hypothesized that
similar results would be obtained with DC1 mobilized by Flt3L.
Unexpectedly, we found that immature DC expanded in vivo by Flt3L
treatment could not be stimulated to produce IL-12 in vitro using CD40L
and/or interferon-
(IFN-
) alone. Instead, we found that
Flt3L-mobilized DC from cancer patients require a sequence of specific
signals for maturation, which included initial treatment with
granulocyte macrophage-colony stimulating factor followed by a
combination of maturation signals such as CD40L and IFN-
.
Flt3L-mobilized DC matured in this manner possessed greater T
cell-stimulatory function than nonmatured DC. The ability to generate
phenotypically mature, IL-12-producing DC1 from peripheral blood
mononuclear cells mobilized by Flt3L will have important implications
for the development of effective cancer immunotherapy
strategies.
Key Words: IFN-
CD40 ligand IL-12 GM-CSF immunotherapy
This article has been cited by other articles:
![]() |
B. J. Masten, G. K. Olson, D. F. Kusewitt, and M. F. Lipscomb Flt3 Ligand Preferentially Increases the Number of Functionally Active Myeloid Dendritic Cells in the Lungs of Mice J. Immunol., April 1, 2004; 172(7): 4077 - 4083. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Jefford, M. Schnurr, T. Toy, K.-A. Masterman, A. Shin, T. Beecroft, T. Y. Tai, K. Shortman, M. Shackleton, I. D. Davis, et al. Functional comparison of DCs generated in vivo with Flt3 ligand or in vitro from blood monocytes: differential regulation of function by specific classes of physiologic stimuli Blood, September 1, 2003; 102(5): 1753 - 1763. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. E. Toliver-Kinsky, C. Y. Lin, D. N. Herndon, and E. R. Sherwood Stimulation of Hematopoiesis by the Fms-Like Tyrosine Kinase 3 Ligand Restores Bacterial Induction of Th1 Cytokines in Thermally Injured Mice Infect. Immun., June 1, 2003; 71(6): 3058 - 3067. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |